Literature DB >> 20962266

CD20+ B cells: the other tumor-infiltrating lymphocytes.

Brad H Nelson1.   

Abstract

Tumor-infiltrating CD8(+) T cells are strongly associated with patient survival in a wide variety of human cancers. Less is known about tumor-infiltrating CD20(+) B cells, which often colocalize with T cells, sometimes forming organized lymphoid structures. In autoimmunity and organ transplantation, T cells and B cells collaborate to generate potent, unrelenting immune responses that can result in extensive tissue damage and organ rejection. In these settings, B cells enhance T cell responses by producing Abs, stimulatory cytokines, and chemokines, serving as local APCs, and organizing the formation of tertiary lymphoid structures that sustain long-term immunity. Thus, B cells are an important component of immunological circuits associated with persistent, rampant tissue destruction. Engagement of tumor-reactive B cells may be an important condition for generating potent, long-term T cell responses against cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962266     DOI: 10.4049/jimmunol.1001323

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  156 in total

Review 1.  Medulloblastoma-biology and microenvironment: a review.

Authors:  Tiara Byrd; Robert G Grossman; Nabil Ahmed
Journal:  Pediatr Hematol Oncol       Date:  2012-06-28       Impact factor: 1.969

2.  PD-1 Blockade Expands Intratumoral Memory T Cells.

Authors:  Antoni Ribas; Daniel Sanghoon Shin; Jesse Zaretsky; Juliet Frederiksen; Andrew Cornish; Earl Avramis; Elizabeth Seja; Christine Kivork; Janet Siebert; Paula Kaplan-Lefko; Xiaoyan Wang; Bartosz Chmielowski; John A Glaspy; Paul C Tumeh; Thinle Chodon; Dana Pe'er; Begoña Comin-Anduix
Journal:  Cancer Immunol Res       Date:  2016-01-19       Impact factor: 11.151

Review 3.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

Review 4.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

5.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

6.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Authors:  Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 8.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

9.  Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.

Authors:  Jiusheng Deng; Shala Yuan; Andrea Pennati; Jordan Murphy; Jian Hui Wu; David Lawson; Jacques Galipeau
Journal:  Cancer Res       Date:  2014-06-17       Impact factor: 12.701

10.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.